Surgical Site Infection
Conditions
Keywords
cohort, visceral surgery, biobank
Brief summary
Personalizing surgical care is of enormous clinical relevance, when considering the number of patients undergoing surgery in Switzerland every year. Currently, personalization is based on underlying or coexisting disease or alterations of laboratory values, but there is no accepted biological test available that may predict success or failure of surgery. Surgical site infections are the most common form of hospital-acquired infections. While the relevance of bacteria, antibiotics and intensive care support is well accepted, the impact of the individual host response remains poorly understood. The Investigators hypothesize that postoperative alterations of the metabolome allow identification of predictors of surgical complications in general, and surgical site infections in particular.
Detailed description
The investigators will conduct a prospective cohort study aiming to identify the metabolic and genetic signature that is associated with surgical site infections. Secondary aims and outcomes include the influence of metabolome on response to anesthetic drugs and acute and chronic pain, surgery- and anesthesia-factors related to short- and long-term oncological outcome, metabolic response effect on infectious complications and rejection after transplantation, bacteria-specific immune responses to major surgery after 2-4 weeks after surgery, metabolomics and macrobiotic markers for postoperative ileus or anastomotic leakage, and the effect of the presence of multidrug resistant bacteria on surgical outcome. All patients undergoing surgery in the investigators' clinic and who gave informed consent will be included. A blood sample will be taken before surgery, on the first postoperative day and after 3-8 weeks. A Urine sample will be taken after surgery and after 3-8 weeks. Sink and rectal swabs will be acquired before surgery. The samples will be stored in a Biobank. Additionally, all data routinely captured during the treatment of the patient from the different data collection systems in use in the investigators' hospital will be coded and centralized in a single, cohort database
Interventions
DIAGNOSTIC_TESTBlood and urine samples, skin and stool swabs
Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
Sponsors
Insel Gruppe AG, University Hospital Bern
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients undergoing surgery at the Department of Visceral Surgery and Medicine, Inselspital, University Hospital Bern * Who gave General consent * Study-specific written informed consent
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of surgical site infection | 30 days | Number of patients with surgical site infections 30 days postoperatively |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stool - incidence of surgical site infections | 30 days | Predictive value of preoperative stool sample for surgical site infections |
| Urine - incidence of surgical site infections | 30 days | Predictive value of preoperative urine sample for surgical site infections |
| Blood - incidence of surgical site infections | 30 days | Predictive value of pre and postoperative plasma metabolome for surgical site infections |
| Somatic genomic in surgical site infections | 30 days | Predictive value of somatic genomic variations for surgical site infections |
| Informed Consent | 3 years | Rate of inclusion for informed consenting |
| Biobanking | 3 years | Rate of inclusion for full biobanking |
Countries
Switzerland
Contacts
PRINCIPAL_INVESTIGATORGuido Beldi
Insel Gruppe AG, University Hospital Bern
Outcome results
None listed